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![A 67-year-old woman with no prior history of benign thyroid disease presented with a two month history of fevers, night sweats, and rapidly enlarging neck mass. Biopsy of the right thyroid lobe revealed a diffuse large B-cell lymphoma (DLBCL). A staging ^18^F-fluoro-2-deoxy-D-glucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) (Discovery-ST, GE Healthcare, WI, USA) was performed and maximum intensity projection (MIP) images, (A) anterior and (B) left lateral, showed a large intensely ^18^F-FDG avid mass in the right neck with no distant metastases.](MIRT-27-41-g1){#f1}

![(A, B) Transaxial and (C) coronal views of the neck with CT (left), PET (middle), and PET/CT fusion (right) images show right thyroid DLBCL, measuring 13x9 cm with maximum standardized uptake value (SUV~max~) 54, compressing the trachea to a narrow slit left of the midline.](MIRT-27-41-g2){#f2}

![The patient was treated with 3 cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) followed by external beam radiation therapy. The first follow-up PET/CT was performed 3 months after the end of radiation therapy and MIP views, (A) anterior and (B) left lateral, show a dramatic reduction in the size of right thyroid DLBCL and resolution of tracheal compression with persistently intense ^18^F-FDG uptake in both thyroid lobes with SUV~max~ 8.9 on the right. These findings were interpreted as partial response to therapy, however since the patient was asymptomatic, a conservative management approach was taken.](MIRT-27-41-g3){#f3}

![(A) Transaxial and (B) coronal views of the post therapy PET/CT showing apparent partial response to therapy.](MIRT-27-41-g4){#f4}

![A second follow-up PET/CT was performed one year later. SUVmax of right thyroid lobe was 10.2, unchanged according to PET Response Criteria in Solid Tumors (PERCIST 1.0). The pattern of 18F-FDG uptake and distribution in the thyroid gland were also unchanged. Biopsy of both thyroid lobes revealed thyroiditis with no evidence of residual lymphoma. A third follow-up PET/CT was performed 2 years later and SUVmax in the right thyroid lobe was 9.5 (unchanged according to PERCIST) with stable pattern of 18F-FDG uptake and distribution, consistent with remission. Primary thyroid lymphoma makes up 1-5% of thyroid malignancies and less than 2% of extranodal lymphomas ([@ref1]). It is more common in women, and patients present in the seventh decade of life with rapidly enlarging neck mass ([@ref1],[@ref2],[@ref3],[@ref4]). The use of 18F-FDG PET/CT to stage primary thyroid lymphoma and evaluate response to therapy has been previously reported in the literature ([@ref5],[@ref6]). Recent studies have raised concern about high rate of false positives on PET/CT performed following therapy for thyroid lymphoma, although these have been attributed to Hashimoto's thyroiditis ([@ref7],[@ref8],[@ref9],[@ref10],[@ref11],[@ref12]). External beam radiation therapy can produce both inflammatory and proliferative changes in the thyroid gland with increases in macrophage populations ([@ref9],[@ref10]). Studies have shown that ^18^F-FDG uptake is increased in head and neck soft tissues affected by such inflammatory and proliferative processes and lasts several months after the completion of radiation therapy ([@ref11],[@ref12],[@ref10]). The present case is an example of a long-term post-treatment thyroiditis, which remained intensely ^18^F-FDG avid but stable on several follow-up PET/CTs spanning three years, which to our knowledge has not been previously reported in the literature.](MIRT-27-41-g5){#f5}
